Search Results

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of The State of Oregon Agriculture Fertilizer Registration Certificate

AviadoBio today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University.

RaySearch Laboratories AB announces that Oregon Health & Science University in the USA has placed an order for the treatment planning system RayStation®*.

Skanska has signed an additional contract with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.

Lantern Pharma Inc. announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.